Skip to main content
SpringerLink
Log in

Is There a Role for Immunotherapy in Osteosarcoma?

  • Chapter
  • First Online:
Pediatric and Adolescent Osteosarcoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 152))

Abstract

With the introduction of effective systemic chemotherapy, the prognosis for patients with osteosarcoma has improved dramatically. Estimates of overall survival for osteosarcoma patients prior to 1975 ranged from 5 to 20%, even for patients with localized disease of the extremity treated with amputation. The majority of these patients eventually developed pulmonary metastases and succumbed to their disease. The introduction of effective chemotherapy has dramatically improved the outcome of patients with localized disease, but has not altered the survival of patients with metastatic disease. Moreover, there has been little, if any, improvement in the outcomes of patients with localized disease since the mid-1980s. This has led to the investigation of other treatment approaches, including immunotherapy. Coincident with the initial development of chemotherapy, there were early attempts at immunotherapy. These met with little success. Subsequent approaches to harnessing the immune system have yielded more encouraging results. This chapter will review these various approaches, highlighting the role that immunotherapy might play in the multi-modality treatment of localized and metastatic osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eilber FR, Morton DL. Demonstration in sarcoma patients of anti-tumor antibodies which fix only human complement. Nature. 1970;225(5238):1137-1138.

    Article  CAS  PubMed  Google Scholar 

  2. Eilber FR, Morton DL. Sarcoma-specific antigens: detection by complement fixation with serum from sarcoma patients. J Natl Cancer Inst. 1970;44(3):651-656.

    CAS  PubMed  Google Scholar 

  3. Wood WC, Morton DL. Microcytotoxicity test: detection in sarcoma patients of antibody cytotoxic to human sarcoma cells. Science. 1970;170(964):1318-1320.

    Article  CAS  PubMed  Google Scholar 

  4. Theoleyre S, Mori K, Cherrier B, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer. 2005;5:123.

    Article  CAS  PubMed  Google Scholar 

  5. Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother. 2007;56(7):1037-1046.

    Article  PubMed  Google Scholar 

  6. Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64(3):529-564.

    Article  CAS  PubMed  Google Scholar 

  7. Marsh B, Flynn L, Enneking W. Immunologic aspects of osteosarcoma and their application to therapy. A preliminary report. J Bone Joint Surg Am. 1972;54(7):1367-1397.

    CAS  PubMed  Google Scholar 

  8. Eilber FR, Grant T, Morton DL. Adjuvant therapy for osteosarcoma: preoperative and postoperative treatment. Cancer Treat Rep. 1978;62(2):213-216.

    CAS  PubMed  Google Scholar 

  9. Friedl P, Storim J. Diversity in immune-cell interactions: states and functions of the immunological synapse. Trends Cell Biol. 2004;14(10):557-567.

    Article  CAS  PubMed  Google Scholar 

  10. Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8–5. Cancer Sci. 2006;97(12):1374-1380.

    Article  CAS  PubMed  Google Scholar 

  11. Yu Z, Ma B, Zhou Y, Zhang M, Qiu X, Fan Q. Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma. Exp Oncol. 2005;27(4):273-278.

    CAS  PubMed  Google Scholar 

  12. Gilchrist GS, Ivins JC, Ritts RE Jr, Pritchard DJ, Taylor WF, Edmonson JM. Adjuvant therapy for nonmetastatic osteogenic sarcoma: an evaluation of transfer factor versus combination chemotherapy. Cancer Treat Rep. 1978;62(2):289-294.

    CAS  PubMed  Google Scholar 

  13. Spitler LE, Miller L. Clinical trials of transfer factor in malignancy. J Exp Pathol. 1987;3(4):549-564.

    CAS  PubMed  Google Scholar 

  14. Jaffe N, Frei E 3rd, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974;291(19):994-997.

    Article  CAS  PubMed  Google Scholar 

  15. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 1995;34(6):877-880.

    Article  CAS  PubMed  Google Scholar 

  16. Muller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 2005;44(5):475-480.

    Article  PubMed  Google Scholar 

  17. Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep. 2002;4(6):510-514.

    Article  PubMed  Google Scholar 

  18. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10(8):1310-1316.

    CAS  PubMed  Google Scholar 

  19. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81(12):935-938.

    Article  CAS  PubMed  Google Scholar 

  20. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18(2):93-99.

    Article  CAS  PubMed  Google Scholar 

  21. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004-2011.

    Article  CAS  PubMed  Google Scholar 

  22. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol. 2008;26(4):633-638.

    Article  CAS  PubMed  Google Scholar 

  23. Rao RD, Anderson PM, Arndt CA, Wettstein PJ, Markovic SN. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol. 2003;26(5):493-498.

    Article  CAS  PubMed  Google Scholar 

  24. Duan X, Zhou Z, Jia SF, Colvin M, Lafleur EA, Kleinerman ES. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res. 2004;10(2):777-783.

    Article  CAS  PubMed  Google Scholar 

  25. Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res. 2003;9(9):3462-3468.

    CAS  PubMed  Google Scholar 

  26. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002;9(3):260-266.

    Article  CAS  PubMed  Google Scholar 

  27. Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer. 2006;106(6):1382-1388.

    Article  CAS  PubMed  Google Scholar 

  28. Liebau C, Merk H, Schmidt S, et al. Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol Ther. 2002;7(4):135-142.

    Article  CAS  PubMed  Google Scholar 

  29. Sutherland CM, Krementz ET, Hornung MO, Carter RD, Holmes J. Transfer of in vitro cytotoxicity against osteogenic sarcoma cells. Surgery. 1976;79(6):682-685.

    CAS  PubMed  Google Scholar 

  30. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17(9):2781-2788.

    CAS  PubMed  Google Scholar 

  31. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res. 2001;382:59-65.

    Article  PubMed  Google Scholar 

  32. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res. 2002;8(3):788-793.

    CAS  PubMed  Google Scholar 

  33. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer. 2005;41(9):1349-1361.

    Article  CAS  PubMed  Google Scholar 

  34. Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol. 2005;8(5):525-532.

    Article  CAS  PubMed  Google Scholar 

  35. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer. 2007;43(16):2339-2344.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology and Pediatrics, Musculoskeletal Tumor Program, Johns Hopkins University, Bunting-Blaustein Cancer Research Building, Room 2M51, 1650 Orleans St, Baltimore, MD, 21231, USA

    David M. Loeb

Authors
  1. David M. Loeb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Loeb .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, University of Texas, Holcombe Blvd. 1515, Houston, 77030-4095, U.S.A.

    Norman Jaffe

  2. Dept. Medical Oncology, Norwegian Radium Hospital, Ullernschaussee 70, Oslo, 0310, Norway

    Oyvind S. Bruland

  3. Orthopädische Klinik, Olgahospital, Bismarckstraße 8, Stuttgart, 70176, Germany

    Stefan Bielack

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Loeb, D.M. (2009). Is There a Role for Immunotherapy in Osteosarcoma?. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0284-9_25

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-0283-2

  • Online ISBN: 978-1-4419-0284-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation